According to recent HF guidelines this include renin angiotensin aldosterone system (RAAS) inhibitors, beta blockers (BB), mineralocorticoid receptor antagonists (MRA), and sodium glucose cotransporter 2 (SGLT2) inhibitors in all symptomatic HFrEF patients [5,6,7]. This evidence concerns the gene SLC5A2 and hydrops fetalis.